SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
暂无分享,去创建一个
Kamlesh Khunti | K. Khunti | X. Cos | S. Seidu | S. Kunutsor | Samuel Seidu | Setor K. Kunutsor | Xavier Cos | Syed Gillani | S. Gillani
[1] H. Häring,et al. Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2014, Diabetes Care.
[2] A. Kashiwagi,et al. Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study , 2015, Diabetology International.
[3] G. Bakris,et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease , 2013, Diabetes, obesity & metabolism.
[4] C. Bailey,et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.
[5] A. Mithal,et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. , 2014, The lancet. Diabetes & endocrinology.
[6] Lawrence A Leiter,et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial , 2013, The Lancet.
[7] J. Kullberg,et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. , 2012, The Journal of clinical endocrinology and metabolism.
[8] C. Kovacs,et al. Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial , 2014, Diabetes, obesity & metabolism.
[9] John M Lachin,et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.
[10] K. Mahaffey,et al. Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes , 2014, Diabetes Care.
[11] G. Charpentier,et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial , 2013, International journal of clinical practice.
[12] E. Ferrannini,et al. Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise , 2010, Diabetes Care.
[13] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[14] J. Rosenstock,et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial , 2015, Diabetes, obesity & metabolism.
[15] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.
[16] J. McGill,et al. Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment , 2013, Diabetes Care.
[17] J. Shaw,et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. , 2014, Diabetes Research and Clinical Practice.
[18] Y. Terauchi,et al. Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial , 2014, Advances in Therapy.
[19] Zhongxin Zhang,et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.
[20] Jesse C. Crosson,et al. Medical costs associated with type 2 diabetes complications and comorbidities. , 2013, The American journal of managed care.
[21] P. Norwood,et al. A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers , 2009, Diabetes Care.
[22] Enrique Morales,et al. Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes , 2008, Diabetes Care.
[23] E. Ferrannini,et al. A Phase IIb, randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes , 2013, Diabetes, obesity & metabolism.
[24] Y. Seino,et al. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study , 2014, Current medical research and opinion.
[25] Y. Terauchi,et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study , 2014, Cardiovascular Diabetology.
[26] R. Henry,et al. SGLT2 inhibition — a novel strategy for diabetes treatment , 2010, Nature Reviews Drug Discovery.
[27] K. Kim,et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise , 2013, Diabetes, obesity & metabolism.
[28] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[29] G. Bakris,et al. Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy , 2014, American Journal of Nephrology.
[30] S. Del Prato,et al. Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin , 2011, Diabetes Care.
[31] D. Kohan,et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control , 2013, Kidney international.
[32] J. Chan,et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency , 2008, Diabetes, obesity & metabolism.
[33] M. Haneda,et al. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. , 2016, Clinical therapeutics.
[34] S. Dejager,et al. Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment , 2013, Diabetes Therapy.
[35] K. Yoon,et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial , 2011, Diabetes, obesity & metabolism.
[36] P. Groop,et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes , 2016, Diabetologia.
[37] Y. Seino,et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study , 2014, Current medical research and opinion.
[38] J. Rosenstock,et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes , 2014, Diabetes Care.
[39] I. Hozo,et al. Estimating the mean and variance from the median, range, and the size of a sample , 2005, BMC medical research methodology.
[40] H. Bays. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus , 2009 .
[41] K. Mahaffey,et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.
[42] W. Herrington,et al. Metformin use in chronic kidney disease: new evidence to guide dosing. , 2013, QJM : monthly journal of the Association of Physicians.
[43] H. Kramer,et al. Screening for kidney disease in adults with diabetes. , 2005, Diabetes care.
[44] B. Cha,et al. Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial , 2015, Journal of diabetes investigation.
[45] J. Doupis,et al. The renal effects of SGLT2 inhibitors and a mini-review of the literature , 2016, Therapeutic advances in endocrinology and metabolism.
[46] G. Meininger,et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone , 2014, Diabetes, obesity & metabolism.
[47] N. Inagaki,et al. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study , 2014, Expert opinion on pharmacotherapy.
[48] I. Tikkanen,et al. Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension , 2014, Diabetes Care.
[49] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[50] G. Bakris,et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease , 2014, Diabetes, obesity & metabolism.
[51] M. Ridderstråle,et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. , 2014, The lancet. Diabetes & endocrinology.
[52] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[53] D. Mauricio,et al. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain , 2015, The European Journal of Health Economics.
[54] B. Bode,et al. Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized Trial , 2013, Hospital practice.
[55] Varsha G. Vimalananda,et al. The economic consequences of diabetes and cardiovascular disease in the United States , 2010, Reviews in Endocrine and Metabolic Disorders.
[56] U. Broedl,et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. , 2015, Diabetes research and clinical practice.
[57] H. Häring,et al. Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes , 2013, Diabetes Care.
[58] A. Kashiwagi,et al. Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study , 2015, Diabetology International.
[59] J. Rosenstock,et al. Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy , 2012, Diabetes Care.
[60] J. Rosenstock,et al. Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes , 2012, Diabetes Care.
[61] A. Januszewicz,et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial , 2013, Diabetologia.
[62] A. Kashiwagi,et al. Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study) , 2015, Diabetology International.
[63] Y. Seino,et al. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study , 2014, Current medical research and opinion.